Home   About this service   Get the news  
+32 2 743 34 03

 
UCB [BE0003739530 / UCB]

UCB Media Room: Disposal of own shares

INFORMATION REGLEMENTEE


[24/03/2020 | 18:00]
https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUb513=
9PTmAm2ORJ-2Fb7C-2B6ekApYdkbb5alZiqJhY03tPgklKGrw3RsPRobHtmhguj2YlFyicQRRZW=
z3GdslFhWL1-2FhlNwTDpthjFo11ZcBecwpCD1_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7=
KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1=
wb-2FK7gSDI07qqOhOSZAyDQj3MuEZ0ga-2FnL30nAO4NOeHx1Ce38hktVbAzmP4evmCjTDY5MS=
4rq07I1SrnE85FB-2BHYvm-2BWnSdWA3rZa5f7f3AFsFjNDN6zNdHm9jnugwA3XW13fhgot1DEJ=
bh7ocADt7IswIvayTBvVmOQJ-2B1b4vHlZimeudCCdngBptKkWhuJOlSAhqa-2FpkY31EaXnxRg=
wwzcrm0rfEuR1PcotKUlo2vLSwkHKiLUEnzRFvj1cgOeE-3D

** Disposal of own shares
------------------------------------------------------------

Brussels (Belgium), 24 March 2020 =E2=80=93 18:00 (CET) =E2=80=93 regulated=
information

In application of article 8:6 of the Royal Decree executing the new Belgian=
Code of Companies and Associations, UCB SA/NV announces that following exe=
rcises of stock options by its employees, it has disposed of UCB shares OTC=
in view of deliveries of shares to the relevant employees, within the fram=
ework of the Long Term Incentive Program of the UCB Group, as follows:

https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUb513=
9PTmAm2ORJ-2Fb7C-2B6ekApYdkbb5alZiqJhY03tPgkHJiN9P64t1hXmqCVl6CmepIir3WvdUm=
A37ZSpebYOCysjGm5tPkdk2x-2BGfZOSivdCEp_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7=
KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1=
wb-2FK7gSDI07qqOhOSZAyDQj3MuEZ0ga-2FnL30nAO4NOeHx1Ce38hktVbAzmP4evmCjTDY5MS=
4rq07I1SrnE85FB-2BHYvm-2BWnSdWA3rZa5f7f3AKHuO0d7mwhDJWyWFd2wijzUSF-2FCDyEKB=
7myi7n-2FBwsBrPmyNOMp0AV8DwIXZyJMOClWCvKmSst-2FjHfwo2ZGB6pwZsbWhpcI3zUjwsxj=
EbuNBZ0Ur8Hv7b6Eeu1L8TxxK68Tpvo9KOxrbzBvwIJ13eg-3D
=C2=A0
This press release is available on UCB SA/NV=E2=80=99s website via the foll=
owing link (https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQ=
yQ53jATUXZJD59ZUodhGC-2FyJVE-2BjXw-2Fd0j1C70r-2FZ058zOLCiGbx-2FzvKhSzxYKNx1=
8dK5MiuQ-3D-3DC_0i_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bS=
l0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wb-2FK7gSDI07qqOhOSZ=
AyDQj3MuEZ0ga-2FnL30nAO4NOeHx1Ce38hktVbAzmP4evmCjTDY5MS4rq07I1SrnE85FB-2BHY=
vm-2BWnSdWA3rZa5f7f3ABrl77aJLeuT76MBJEXxb77jxHJIUTeSl6z-2B-2BoEk6obHeGUGCKl=
TXv4OSRa-2BCw1wAo7gTY5HwXj-2Fj0pbNrvkvAwgALNdXQvgXJVdrSserIPosVToznfUleQUn1=
Dgy6N3C6wk5DqNoUxEAFjXY-2FYj7xE-3D .

Investor Relations

Antje Witte =C2=A0 =C2=A0 =C2=A0 =C2=A0 =C2=A0
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com

Isabelle Ghellynck,
=C2=A0Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com=C2=A0

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With 7 500 people in approxima=
tely 40 countries, the company generated revenue of =E2=82=AC 4.9 billion i=
n 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twit=
ter: @UCB_news
=C2=A0
Image
Chart 1 Disposal of own shares March 24 2020 (https://u7061146.ct.sendgrid.=
net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUb5139PTmAm2ORJ-2Fb7C-2B6ekApYdkbb=
5alZiqJhY03tPgkHJiN9P64t1hXmqCVl6CmfD6dBW-2Bg0vSdym4t8ndpLM-3DN4Q7_xDPID0vO=
uylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Z=
lf-2FOeoCOG9ekocVj-2F2X9c9g1wb-2FK7gSDI07qqOhOSZAyDQj3MuEZ0ga-2FnL30nAO4NOe=
Hx1Ce38hktVbAzmP4evmCjTDY5MS4rq07I1SrnE85FB-2BHYvm-2BWnSdWA3rZa5f7f3AC-2B1c=
ua-2Ba-2BRCQpBQ9Gv1j323Wqo-2Bxce-2Bf0HA4UY2QmDuwqmuK0jtw-2BB0g8SrgiUQjUPhQP=
UhPjnM9rLJ7xucckXJ-2BwH59df6W6MUDiWLsNomJXQMpAtbn5hmKEPJ-2FkD6T3OmdByB8UgJr=
Emv5uEnKY4-3D GenericFile
200324- Disposal of own shares (https://u7061146.ct.sendgrid.net/ls/click?u=
pn=3D4tNED-2FM8iDZJQyQ53jATUb5139PTmAm2ORJ-2Fb7C-2B6ekApYdkbb5alZiqJhY03tPg=
-2FoLrlGcXDNXyClQ0sQE2T4ZQcGsXPhGPBWHfETYVjO8-3DSRHO_xDPID0vOuylFAU8fv4e60w=
ei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ek=
ocVj-2F2X9c9g1wb-2FK7gSDI07qqOhOSZAyDQj3MuEZ0ga-2FnL30nAO4NOeHx1Ce38hktVbAz=
mP4evmCjTDY5MS4rq07I1SrnE85FB-2BHYvm-2BWnSdWA3rZa5f7f3AB0do2decMyWLydLCSoiz=
XkV1z48GaTDGqwxCz5hWhkCqE8m3TlnoMC2EFr9L07HKpQMAEUf7eiNd4cPJL04uGVgnzo3H9KH=
4qTnotyph5vwjlF2EoWSDkhGv8xGXWf5uGl-2FdO5wmytidU9JtrfxfN4-3D GenericFile
200324 - Ali=C3=A9nation d actions propres (https://u7061146.ct.sendgrid.ne=
t/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUb5139PTmAm2ORJ-2Fb7C-2B6ekApYdkbb5a=
lZiqJhY03tPg1xWNx-2BJfyLKCQfswery1ws8FWEmT1JTkqXe-2F8QacKhc-3Dmgz8_xDPID0vO=
uylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Z=
lf-2FOeoCOG9ekocVj-2F2X9c9g1wb-2FK7gSDI07qqOhOSZAyDQj3MuEZ0ga-2FnL30nAO4NOe=
Hx1Ce38hktVbAzmP4evmCjTDY5MS4rq07I1SrnE85FB-2BHYvm-2BWnSdWA3rZa5f7f3AMAH-2B=
w7NqB2o00hD4WGpqmzpgMg4SLodVlNBDwDXoZw-2B4lZ3gMveweVABtyxsPBr4tOClh8-2FEhOt=
FI8OZGiApT7JbJitWUBNWbBNh3a00XkvDSGns77oSWCXkOh4L1CjrHBfPrQvwGfkxTNRgHqKzFo=
-3D GenericFile
200324- Vervreemding van eigen aandelen (https://u7061146.ct.sendgrid.net/l=
s/click?upn=3D4tNED-2FM8iDZJQyQ53jATUb5139PTmAm2ORJ-2Fb7C-2B6ekApYdkbb5alZi=
qJhY03tPgZDOzda-2BONd7IL4tsEcIstwB94OXGPpbwe5cTqN2yYa0-3Dggs9_xDPID0vOuylFA=
U8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2F=
OeoCOG9ekocVj-2F2X9c9g1wb-2FK7gSDI07qqOhOSZAyDQj3MuEZ0ga-2FnL30nAO4NOeHx1Ce=
38hktVbAzmP4evmCjTDY5MS4rq07I1SrnE85FB-2BHYvm-2BWnSdWA3rZa5f7f3AG-2BRt1ycZF=
J0HFI8fWuXc2NKZiUnvy4EXBZaRlDqxUcz3gEgm3Ldv00DW3S3MJaPYiVZVR5Bg9qaTM0PA8zCC=
I0wg-2BWoRzkHTVNk53wX-2FIBw73PTFqjkqBShjFlSw9AlXcPwWTnbn2qCdzMFt62dEqs-3D=
=0D
=0D
______________________=0D
If you would rather not receive future communications from UCB SA, please g=
o to https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jAT=
UeYfdhr1xEBQnaPhR2RKx1tfe2VKDZTewv5u80JomRcXsvFKz3DC4Ji0vQITuVkXQLhdulc8VJj=
-2Bl0npvkGfSvg-2B3geKRFw7W0RVkfN1BehVIXUvsdcu8ikTYDQRYE5Jmc2IFSOM5-2BTr0IGs=
pMMsmJ8-3DZpD8_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0Kx=
vPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wb-2FK7gSDI07qqOhOSZAyDQ=
j3MuEZ0ga-2FnL30nAO4NOeHx1Ce38hktVbAzmP4evmCjTDY5MS4rq07I1SrnE85FB-2BHYvm-2=
BWnSdWA3rZa5f7f3AOhhDol9hzhA-2BKAVRvHnCAU1u3S4SAcsfI61lDRpDTxNzZi-2BLGyoGPe=
i52g-2BMPbo1IMFiuf52GIHgNTX-2B7C-2B8BuB-2FkTT3sk0lxTL8ZpQ0M2m2nw1ZTb-2BRZ2u=
hqUa1fsHqQuKIGpA-2B22gk0Z7fcC7MCY-3D=0D
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=